Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC

GlobeNewswire June 15, 2018

Insmed to Present at Three June Conferences

GlobeNewswire June 7, 2018

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Benzinga.com  May 23, 2018

Insmed Appoints Leo Lee to its Board of Directors

GlobeNewswire May 17, 2018

Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC

GlobeNewswire May 16, 2018

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Benzinga.com  May 2, 2018

Insmed Reports First Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire May 2, 2018

Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference

GlobeNewswire May 1, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Benzinga.com  April 29, 2018

35 Biggest Movers From Yesterday

Benzinga.com  April 24, 2018

28 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  April 23, 2018

Mid-Morning Market Update: Markets Mostly Flat; Hasbro Misses Q1 Expectations

Benzinga.com  April 23, 2018

Research Report Identifies Brown & Brown, CorVel, Pacific Ethanol, HomeTrust Bancshares, FORTERRA INC, and Insmed with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire April 5, 2018

Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC

GlobeNewswire March 29, 2018

Insmed to Present at the Cowen and Company 38th Annual Health Care Conference

GlobeNewswire March 7, 2018

Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

GlobeNewswire February 23, 2018

Insmed Incorporated to Host Earnings Call

Accesswire February 23, 2018

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 21, 2018

Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent

GlobeNewswire February 20, 2018

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Benzinga.com  February 19, 2018
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested